M2 Archive: Preview

You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.


Milan - Recordati announces that the European Commission has granted marketing authorisation for the orphan medicinal product Isturisa® (osilodrostat), indicated for the treatment of endogenous Cushing's syndrome (CS) in adults. The active substance of Isturisa® is osilodrostat, a cortisol...  

If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search